JPMorgan lowered the firm’s price target on Moderna (MRNA) to $45 from $59 and keeps an Underweight rating on the shares. The firm updated estimates for the company and refreshed its script trend analysis for the COVID vaccines. While the start of the U.S. vaccination season was pulled forward compared to 2023, the overall the peak is lower based on COVID vaccine trends up to mid-November, the analyst tells investors in a research note.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on MRNA:
- QQQ ETF Update, 11/26/2024
- Early notable gainers among liquid option names on November 25th
- VOO ETF Update, 11/25/2024
- Moderna up as Jefferies suggests ‘peak RFK negativity’ may have been reached
- Trump Trade: Trump Media considers developing crypto payment service
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
